Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MESI-STRAT

Financiado

Cerrado

Systems Medicine of Metabolic Signaling Networks A New Concept for Breast Cance...

Systems Medicine of Metabolic Signaling Networks A New Concept for Breast Cancer Patient Stratification Breast cancer (BC) is a complex disease with high prevalence in the EU. 75% of the tumors are estrogen receptor-positive (ER+), and are treated with endocrine therapies (ET). MESI-STRAT will develop new concepts for knowledge-base... ver más

30/09/2023

UIBK

6M€

Presupuesto del proyecto: 6M€

Líder del proyecto

UNIVERSITAET INNSBRUCK No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 17 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2023-09-30

SC1-PM-02-2017: New concepts in patient stratificat...

I+D

Cerrada hace 8 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

17 Participantes

UIBK

1.64M€ | Lider

HITS

224.69K€ | Participante

MUI

242.48K€ | Participante

CHARITE UNIVERSITAETSMEDIZI...

398.71K€ | Participante

Proyectos interesantes

RTC-2016-5674-1

Medical Technol...

Data Science

482K€ Cerrado

PredAlgoBC

Medical Technol...

Data Science

185K€ Cerrado

MATADOR

Medical Technol...

Data Science

150K€ Cerrado

EpiPredict

Medical Technol...

Data Science

3M€ Cerrado

HD-BRECA

Medical Technol...

Data Science

165K€ Cerrado

BARRICADE

Medical Technol...

Data Science

176K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 70 meses Fecha Inicio: 2017-11-21
Fecha Fin: 2023-09-30

Líder del proyecto

UNIVERSITAET INNSBRUCK No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 6M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Breast cancer (BC) is a complex disease with high prevalence in the EU. 75% of the tumors are estrogen receptor-positive (ER+), and are treated with endocrine therapies (ET). MESI-STRAT will develop new concepts for knowledge-based stratification of patients into subgroups with different ET resistance mechanisms. We will establish predictive models for (1) patient stratification prior and during ET; (2) recurrence risk assessment when ending ET; (3) marker panel development to guide targeted therapies for ET-resistant patients; (4) novel ET resistance mechanism-based therapy design. The unique collection of matched BC tissue, serum, and >10 years follow-up from the patient organization PATH is essential for the longitudinal analysis of ET resistance and relapse. Our team of oncologists, modelers, bioinformaticians and experimentalists will develop new computational models in combination with network analyses and pharmacogenomics, to integrate multi-omics data and explore metabolic and signaling (MESI) networks driving ET resistance. Metabolite marker panels measured in biological fluids will enable patient stratification, resistance monitoring and clinical decision-making. This is a new concept as BC metabolism is poorly explored for diagnostics and therapy. Upon successful validation in preclinical models, the predictive marker panels and related treatments will be jointly investigated by our clinical and industrial partners in clinical studies. Our 3 SMEs will closely co-develop the research, and directly exploit the MESI-STRAT results. BC accounts for the highest cancer-related health-care costs in the EU. Our stratification concepts will increase cost effectiveness and the patients’ quality of life by (1) avoiding ineffective therapies, (2) marker detection in body fluids without surgical interventions, and (3) reducing clinical trial cohorts by improved stratification. This will accelerate the translation of MESI-STRAT results into medical use.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores